Examination of Efficacy and Safety of Baricitinib in RA Patients

Shinshu University90 enrolled

Overview

The aim of this study is to examine the efficacy and adverse events in the following 3 groups in rheumatoid arthritis patients: 1. Baricitinib treatment for 12 months 2. Biologics treatment for 12 months 3. Tofacitinib treatment for 12 months

Study Type

INTERVENTIONAL

Allocation

NON_RANDOMIZED

Purpose

TREATMENT

Masking

SINGLE

Enrollment

Conditions

Rheumatoid Arthritis

Interventions

"Baricitinib", "olumiant®"DRUG

To examine the effects of baricitinib in RA patients

"Biologics"DRUG

To examine the effects of biologics in RA patients

Tofacitinib 5 MG [Xeljanz]DRUG

To examine the effects of tofacitinib in RA patients

Eligibility

Sex: ALLMin age: 20 Years

Medical Language ↔ Plain English

Inclusion Criteria: * RA patients Exclusion Criteria: * Not RA patients * RA patients who are allergic to the drugs, refused to do this research, or who are pregnant

Locations (1)

Yukio Nakamura

Matsumoto, Nagano, Japan

RECRUITING

Outcomes

Primary Outcomes

Assessment of Disease Activity in rheumatoid patients for 1 year treated by baricitinib (N=30), biologics (N=30), or tofacitinib (N=30). Also, the efficacy and adverse event of each drug for 1 year in the RA patients.

Time frame: Change from Baseline Values of DAS28-CRP at 1 year in each group

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.